[1]
|
B. Dean, N. Barber and M. Schachter, “What Is a Prescribing Error?” Quality in Health Care, Vol. 9, 2000, pp. 232-237. doi:10.1136/qhc.9.4.232
|
[2]
|
R. Quinzler, C. Gasse, A. Schneider, P. Kaufmann-Kolle, J. Szecsenyi and W. Haefeli, “The Frequency of Inappropriate Tablet Splitting in Primary Care,” European Journal of Clinical Pharmacology, Vol. 62, No. 12, 2006, pp. 1065-1073. doi:10.1007/s00228-006-0202-3
|
[3]
|
N. Rodenhuis, P. De Smet and D. Barends, “The Rationale of Scored Tablets as Dosage Form,” European Journal of Pharmaceutical Sciences, Vol. 21, No. 2-3, 2004, pp. 305-308. doi:10.1016/j.ejps.2003.10.018
|
[4]
|
R. Quinzler and W. Haefeli, “Tabletten Teilen,” Therapeutische Umschau, Vol. 63, 2006, pp. 441-447.
doi:10.1024/0040-5930.63.6.441
|
[5]
|
R. Quinzler, W. Haefeli, “Zerkleinern von Tabletten,” TMJ, 2008, pp. 44-47.
|
[6]
|
E. van Santen, D. Barends and H. Frijlink, “Breaking of Scored Tablets: A Review,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 53, No. 2, 2002, pp. 139-145. doi:10.1016/S0939-6411(01)00228-4
|
[7]
|
P. Gupta and K. Gupta, “Broken Tablets: Does the Sum of the Parts Equal the Whole?” American Journal of Health-System Pharmacy, Vol. 45, No. 7, 1988, p. 1498.
|
[8]
|
Australian Pharmaceutical Advisory Council, “Guidelines for Medi-cation Management in Residential Aged Care Facilities,” 3rd Edition, Commonwealth of Australia, 2002.
|
[9]
|
J. G. Schier, M. A. Howland, R. S. Hoffman and L. S. Nelson, “Fatality from Administration of Labetalol and Crushed Extended-Release Nifedipine,” Annals of Pharmacotherapy, Vol. 37, No. 10, 2003, pp. 1420-1423.
doi:10.1345/aph.1D091
|
[10]
|
“Summary of Product Information of Puri-Nethol? Tablets 50 mg,” 2012. www.compendium.ch
|
[11]
|
D. Bates, D. J. Cullen, N. Laird, L. Petersen, S. Small, D. Servi, G. Laffel, B. Sweitzer, B. Shea and R. Hallisey, “Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention,” Journal of American Medical Association, Vol. 274, No. 1, 1995, pp. 29-34. doi:10.1001/jama.274.1.29
|
[12]
|
J. K. Aronson, “Medica-tion Errors: Definitions and Classification,” British Journal of Clinical Pharmacology, Vol. 67, No. 6, 2009, pp. 599-604.
doi:10.1111/j.1365-2125.2009.03415.x
|
[13]
|
P. J. Lewis, T. Dornan, D. Taylor, M. P. Tully, V. Wass and D. M. Ashcroft, “Prevalence, Incidence and Nature of Prescribing Errors in Hospital Inpatients: A Systematic Review,” Drug Safety, Vol. 32, 2009, pp. 379-389.
doi:10.2165/00002018-200932050-00002
|
[14]
|
American Society of Health-System Pharmacists, “ASHP Standard Definition of a Medication Error,” American Journal of Hospital Pharmacy, Vol. 39, No. 2, 1982, p. 321.
|
[15]
|
T. Lesar, L. Briceland and D. Stein, “Factors Related to Er-rors in Medication Prescribing,” Journal of the American Medical Association, Vol. 277, 1997, pp. 312-317.
doi:10.1001/jama.277.4.312
|
[16]
|
E. Arques-Armoiry, D. Cabelguenne, C. Stamm, A. Janoly-Dumenil, I. Gros-set-Grange, N. Vantard, P. Maire and B. Charpiat, “Most Frequent Drug-Related Events Detected by Pharmacists during Prescription Analysis in a University Hospital,” La Revue de Médecine Interne, Vol. 31, No. 12, 2010, pp. 804-811.
doi:10.1016/j.revmed.2010.08.001
|
[17]
|
Arzneimittelkompendium der Schweiz Online, 2012.
www.compendium.ch
|
[18]
|
D. Bornand, “Zerm?rserbar-keit und Verabreichungshinweise von Tabletten,” 2008.
www.spitalpharmazie-basel.ch/dienstleistungen/pdf/Zermoerserbarkeit_Tabletten.pdf
|
[19]
|
Anonymous, “Teilbarkeit von Tabletten und Filmtabletten,” Swissmedic, Merkblatt, 2004.
|
[20]
|
R. Quinzler, S. Schmitt, M. Pritsch, J. Kalt-schmidt and W. E. Haefeli, “Substantial Reduction of Inappropriate Tablet Splitting with Computerised Decision Support: A Prospective Intervention Study Assessing Potential Benefit and Harm,” BMC Medical Informatics and Decision Making, Vol. 9, 2009, p. 30.
|
[21]
|
T. Lesar, L. L. Briceland, K. Delcoure, J. Parmalee, V. Masta-Gornic and H. Pohl, “Medication Prescribing Errors in a Teaching Hospital,” Journal of the American Medical Association, Vol. 263, 1990, pp. 2329-2334.
doi:10.1001/jama.263.17.2329
|
[22]
|
N. Drewett, “Stop Regular Medicines Error,” Journal of Pharmacy Practice, Vol. 8, 1998, pp. 193-196.
|
[23]
|
S. Dobrzanski, I. Hammond, G. Khan and H. Holdsworth, “The Nature of Hospital Prescribing Errors,” British Journal of Clinical Governance, Vol. 7, No. 3, 2002, pp. 187-193. doi:10.1108/14664100210438271
|
[24]
|
S. O. Delgado, P. J. Nicolás, L. I. Martínez, F. A. Serrano, J. L. Anoz and C. F. Fernández, “Reconciliation Errors at Admission and Departure in Old and Polymedicated Patients. Prospective, Multicenter Randomized Study,” Medicina Clínica, Vol. 133, 2009, pp. 741-744.
|
[25]
|
G. Schumock, A. Guenette, T. Keys and R. Hutchinson, “Prescribing Errors for Patients about to Be Discharged from a University Teaching Hospital,” American Journal of Hospital Pharmacy, Vol. 51, No. 18, 1994, pp. 2288- 2290.
|
[26]
|
K. B. Johnson, J. K. Butta, P. K. Donohue, D. J. Glenn and N. A. Holtzman, “Discharging Patients with Prescriptions Instead of Me-dications: Sequelae in a Teaching Hospital,” Pediatrics, Vol. 97, No. 4, 1996, pp. 481-485.
|
[27]
|
R. Shawahna and Nisar-Ur-Rahman, “Prescribing Errors Involved Splitting of Tablets: A Two-Hospital Case Analysis,” Pakistan Journal of Medical and Health Sciences, Vol. 2, 2008, pp. 54-58.
|
[28]
|
M. Rupp, M. DeYoung and S. Schondel-meyer, “Prescribing Problems and Pharmacist Interventions in Community Practice,” Medical Care, Vol. 30, No. 10, 1992, pp. 926-940. doi:10.1097/00005650-199210000-00005
|
[29]
|
I. Arnet and K. Hersberger, “Misleading Score-Lines on Tablets: Facilitated Intake or Fractional Dosing?” Swiss Med Weekly, Vol. 140, 2010, pp. 105-110.
|
[30]
|
J. Bachynsky, C. Wiens and K. Melnychuk, “The Practice of Splitting Tablets: Cost and Therapeutic Aspects,” PharmacoEconomics, Vol. 20, 2002, pp. 339-346.
doi:10.2165/00019053-200220050-00005
|
[31]
|
R. S. Stafford and D. C. Radley, “The Potential of Pill Splitting to Achieve Cost Savings,” American Journal of Managed Care, Vol. 8, 2002, pp. 706-712.
|
[32]
|
Royal Pharma-ceutical Society, “Guidance on the Pharmaceutical Issues When Crushing, Opening or Splitting Oral Dosage Forms,” 2011.
www.rpharms.com/pharmacy-practice-resource/specials.asp
|
[33]
|
A. Maher, M. Maglione, S. Bagley, M. Suttorp, J. Hu, B. Ewing, Z. Wang, M. Timmer, D. Sultzer and P. Shekelle, “Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-Analysis,” Journal of the American Medical Association, Vol. 306, 2011, pp. 1359- 1369. doi:10.1001/jama.2011.1360
|
[34]
|
J. Devlin, R. Roberts, J. Fong, Y. Skrobik, R. Riker, N. Hill, T. Robbins and E. Garpestad, “Efficacy and Safety of Quetiapine in Critically Ill Patients with Delirium: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study,” Critical Care Medicine, Vol. 38, No. 2, 2010, pp. 419-427.
doi:10.1097/CCM.0b013e3181b9e302
|
[35]
|
B. Maneeton, N. Maneeton and M. Srisurapanont, “An Open-Label Study of Quetiapine for Delirium,” Journal of the Medical Association of Thailand, Vol. 90, 2007, pp. 2158-2163.
|
[36]
|
C.-U. Pae, S.-J. Lee, C.-U. Lee, C. Lee and I.-H. Paik, “A Pilot Trial of Quetiapine for the Treatment of Patients with Delirium,” Human Psycho-pharmacology, Vol. 19, No. 2, 2004, pp. 125-127. doi:10.1002/hup.559
|
[37]
|
Y. Sasaki, T. Matsuyama, S. Inoue, T. Sunami, T. Inoue, K. Denda and T. Koyama, “A Prospective, Open-Label, Flexible-Dose Study of Quetia-pine in the Treatment of Delirium,” Journal of Clinical Psychiatry, Vol. 64, 2003, pp. 1316-1321. doi:10.4088/JCP.v64n1106
|
[38]
|
M. Onor, M. Saina and E. Aguglia, “Efficacy and Tolerability of Quetiapine in the Treatment of Behavioral and Psychological Symptoms of Dementia,” American Journal of Alzheimer’s Disease & Other Dementias, Vol. 21, No. 6, 2007, pp. 448-453.
doi:10.1177/1533317506294775
|